Ann: AGM Presentation by CEO, page-35

Mal - I agree with your assessment that what is needed is a therapeutic deal. My reason for investing in CDY back in 2014 was based on the Ballieu Holst report which stated "it is unusual for one company to own a whole new target this big". I thought I was investing in a research company which also owned "a small but growing business selling hair restoration products". We were to go to the clinic in the first half of 2015 with an anti-midkine antibody in cancer. Their valuations were $0.07 base case and $0.26 optimistic case (I wish). Somewhere along the way we seem to have changed focus and whilst the Advangen business is going gangbusters I agree that some action by the other sections of the business is required to get the share price moving.